Figure 7

Enhanced effect of anti-DCD rabbit polyclonal antibodies and trastuzumab combination on growth and tumor formation of MDA-MB-361 cellsin vitroandin vivo. A, Quantitative analysis of colony numbers observed 72 hours after inoculation of MDA-MB-361 cells in 96-well plates in the presence of 10% BFS (black column 1) or in the presence of 1% BFS plus non-specific antibodies (white column 1), or 1% BFS in the presence of non-specific antibody (black column 2, 3 and 4) or presence of the antibodies trastuzumab (20 mg/kg), a mixture of goat polyclonal anti-DCD antibodies or their mixture at final concentration of 100 μg/ml. Colonies numbers with ≥5 cells/colony were counted manually in at least 10 fields. Results are given as means ± SD of three experiments and statistical difference (p < 0,05) were determined by Student t test. B, Fold-increase in the volume of MDA-MB-361 xenograft tumors growing in mice (4–5 animal in each group) untreated or treated with weekly i.p. doses of trastuzumab (20 mg/kg), a mixture of goat polyclonal anti-DCD antibodies (1 mg/kg), named N-20, A-20 and S-19 or their combination for a five weeks. Statistical difference (p < 0,05) were determined by One-way ANOVA with Turkey’s pairwise comparisons.